Japan approved AstraZeneca's long-lasting antibody complex Evusheld for the first time in the world for COVID-19 treatment. On the 30th (local time), Ministry of Health, Labour and Welfare of Japan approved the Evusheld as a prevention of symptomatic diseases caused by COVID-19 infection (pre-exposure prophylactic therapy) and a treatment for symptomatic diseases caused by COVID-19.

Evusheld has been approved for COVID-19 prevention in Korea, the United States, and Europe and is being administered to high-risk groups. Furthermore, Japan allowed Evusheld to be used for treatment for the first time in the world. With the approval, the Japanese government purchased Evusheld for 300,000 people. For preventi